Cybin Logo

Cybin Inc.

NEO: CYBN  NYSE American: CYBN

Cybin is focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. Cybin’s mission is to revolutionize mental healthcare.

In December 2020, Cybin acquired Adelia Therapeutics, growing their patent filings to over half a dozen applications.

Cybin Inc.
$2.38
-2.46%
$0.0600

The potential of psychedelic therapies to treat mental illness and addiction disorders has never been more significant. With this [$45m] investment, we will continue to advance our robust pipeline of psychedelic-based products through clinical development.

Doug Drysdale, CEO

Join our Newsletter

Get the latest Company updates delivered to straight to your inbox.